当前位置: 首页 >> 检索结果
7045. Estimating lifetime benefits of comprehensive disease-modifying pharmacological therapies in patients with heart failure with reduced ejection fraction: a comparative analysis of three randomised controlled trials.
作者: Muthiah Vaduganathan.;Brian L Claggett.;Pardeep S Jhund.;Jonathan W Cunningham.;João Pedro Ferreira.;Faiez Zannad.;Milton Packer.;Gregg C Fonarow.;John J V McMurray.;Scott D Solomon.
来源: Lancet. 2020年396卷10244期121-128页
Three drug classes (mineralocorticoid receptor antagonists [MRAs], angiotensin receptor-neprilysin inhibitors [ARNIs], and sodium/glucose cotransporter 2 [SGLT2] inhibitors) reduce mortality in patients with heart failure with reduced ejection fraction (HFrEF) beyond conventional therapy consisting of angiotensin-converting enzyme (ACE) inhibitors or angiotensin receptor blockers (ARBs) and β blockers. Each class was previously studied with different background therapies and the expected treatment benefits with their combined use are not known. Here, we used data from three previously reported randomised controlled trials to estimate lifetime gains in event-free survival and overall survival with comprehensive therapy versus conventional therapy in patients with chronic HFrEF.
7047. Variations between women and men in risk factors, treatments, cardiovascular disease incidence, and death in 27 high-income, middle-income, and low-income countries (PURE): a prospective cohort study.
作者: Marjan Walli-Attaei.;Philip Joseph.;Annika Rosengren.;Clara K Chow.;Sumathy Rangarajan.;Scott A Lear.;Khalid F AlHabib.;Kairat Davletov.;Antonio Dans.;Fernando Lanas.;Karen Yeates.;Paul Poirier.;Koon K Teo.;Ahmad Bahonar.;Felix Camilo.;Jephat Chifamba.;Rafael Diaz.;Joanna A Didkowska.;Vilma Irazola.;Rosnah Ismail.;Manmeet Kaur.;Rasha Khatib.;Xiaoyun Liu.;Marta Mańczuk.;J Jaime Miranda.;Aytekin Oguz.;Maritza Perez-Mayorga.;Andrzej Szuba.;Lungiswa P Tsolekile.;Ravi Prasad Varma.;Afzalhussein Yusufali.;Rita Yusuf.;Li Wei.;Sonia S Anand.;Salim Yusuf.
来源: Lancet. 2020年396卷10244期97-109页
Some studies, mainly from high-income countries (HICs), report that women receive less care (investigations and treatments) for cardiovascular disease than do men and might have a higher risk of death. However, very few studies systematically report risk factors, use of primary or secondary prevention medications, incidence of cardiovascular disease, or death in populations drawn from the community. Given that most cardiovascular disease occurs in low-income and middle-income countries (LMICs), there is a need for comprehensive information comparing treatments and outcomes between women and men in HICs, middle-income countries, and low-income countries from community-based population studies.
7051. Epidemiology, clinical course, and outcomes of critically ill adults with COVID-19 in New York City: a prospective cohort study.
作者: Matthew J Cummings.;Matthew R Baldwin.;Darryl Abrams.;Samuel D Jacobson.;Benjamin J Meyer.;Elizabeth M Balough.;Justin G Aaron.;Jan Claassen.;LeRoy E Rabbani.;Jonathan Hastie.;Beth R Hochman.;John Salazar-Schicchi.;Natalie H Yip.;Daniel Brodie.;Max R O'Donnell.
来源: Lancet. 2020年395卷10239期1763-1770页
Over 40 000 patients with COVID-19 have been hospitalised in New York City (NY, USA) as of April 28, 2020. Data on the epidemiology, clinical course, and outcomes of critically ill patients with COVID-19 in this setting are needed.
7052. Electron microscopy of SARS-CoV-2: a challenging task - Authors' reply.
作者: Zsuzsanna Varga.;Andreas J Flammer.;Peter Steiger.;Martina Haberecker.;Rea Andermatt.;Annelies Zinkernagel.;Mandeep R Mehra.;Felix Scholkmann.;Reto Schüpbach.;Frank Ruschitzka.;Holger Moch.
来源: Lancet. 2020年395卷10238期e100页 7056. Remdesivir in adults with severe COVID-19: a randomised, double-blind, placebo-controlled, multicentre trial.
作者: Yeming Wang.;Dingyu Zhang.;Guanhua Du.;Ronghui Du.;Jianping Zhao.;Yang Jin.;Shouzhi Fu.;Ling Gao.;Zhenshun Cheng.;Qiaofa Lu.;Yi Hu.;Guangwei Luo.;Ke Wang.;Yang Lu.;Huadong Li.;Shuzhen Wang.;Shunan Ruan.;Chengqing Yang.;Chunlin Mei.;Yi Wang.;Dan Ding.;Feng Wu.;Xin Tang.;Xianzhi Ye.;Yingchun Ye.;Bing Liu.;Jie Yang.;Wen Yin.;Aili Wang.;Guohui Fan.;Fei Zhou.;Zhibo Liu.;Xiaoying Gu.;Jiuyang Xu.;Lianhan Shang.;Yi Zhang.;Lianjun Cao.;Tingting Guo.;Yan Wan.;Hong Qin.;Yushen Jiang.;Thomas Jaki.;Frederick G Hayden.;Peter W Horby.;Bin Cao.;Chen Wang.
来源: Lancet. 2020年395卷10236期1569-1578页
No specific antiviral drug has been proven effective for treatment of patients with severe coronavirus disease 2019 (COVID-19). Remdesivir (GS-5734), a nucleoside analogue prodrug, has inhibitory effects on pathogenic animal and human coronaviruses, including severe acute respiratory syndrome coronavirus 2 (SARS-CoV-2) in vitro, and inhibits Middle East respiratory syndrome coronavirus, SARS-CoV-1, and SARS-CoV-2 replication in animal models.
|